Salzburg Therapeutics^®

What if anticancer drugs could find their way specifically into cancer cells?  No longer would oncologists have to be burdened with determining how much chemotherapy a patient could safely endure before side-effects would overwhelm the patient.  No longer would cancer patients feel the "cure" was as devasatating as the disease.  Cytotoxamer technology has been developed by Salzburg Therapeutics to specifically recognize and to kill targeted cancer cells - and leaves non-malignant cells unharmed.

How do Cytotoxamers work?  Cancer cells express certain proteins on their surfaces that non-malignant cells do not.  Cytotoxamers are three-dimensional nucleic acid structures that recognize these cancer-specific proteins and become internalized selectively into cancer cells.  After internalization, Cytotoxamers release activated anticancer drugs, like soldiers breaking our from a Trojan Horse, selectively killing malignant cells and leaving non-malignant cells undamaged.  The initial Cytotoxamer product being developed by Salzburg Therapeutics targets prostate-specific membrane antigen - a protein that is specifically expressed by prostate cancer cells and cells that line newly formed blood vessels in tumors.

Cytotoxamer technology can be likened to the ancient Greek myth of the Trojan Horse.  Unable to defeat the Trojan army directly, Greek warriors developed a strategem to hide soldiers within a large wooden horse.  The horse was presented at the gates of Troy and accepted as gift.  That night, Odysseus and other Greek soldiers broke out of the horse and initated battle that resulted in a resounding victory for the Greeks.